MediWound Ltd.
MDWDNext catalyst
EscharEx (EX-03)
Venous Leg Ulcer (VLU)
Get an email about MDWD's next catalysts
Track MediWound (MDWD) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (earnings).See the timeline
2 upcoming, 1 past
MDWD Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.66 | FQ end Sep/2026 | Call: bmo
EscharEx (EX-03) Phase 3 Est. Readout (VALUE)
Primary completion for EscharEx (EX-03) trial (NCT06568627) in Venous Leg Ulcer (VLU)
SourceMarket Overview
Stock performance and key metrics
DGD
Burn
EscharEx (EX-03)
Venous Leg Ulcer (VLU)
NexoBrid
Thermal Burns
EscharEx (EX-02 formulation)
Venous Leg Ulcer
EscharEx
Hard to Heal Wounds
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
DGD | Phase 3 | Burn | - | - |
EscharEx (EX-03) | Phase 3 | Venous Leg Ulcer (VLU) | - | - |
NexoBrid | Phase 3 | Thermal Burns | - | - |
EscharEx (EX-02 formulation) | Phase 2 | Venous Leg Ulcer | - | - |
EscharEx | Phase 2 | Hard to Heal Wounds | - | - |
Frequently asked questions
What is in MediWound Ltd.'s drug pipeline?→
CatalystAlert tracks 5 drug candidates in MediWound Ltd.'s (MDWD) pipeline across Phase 3, Phase 2. Its lead program is EscharEx (EX-03) (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is MediWound Ltd.'s next FDA catalyst?→
MediWound Ltd.'s (MDWD) next tracked catalyst is a Phase 3 readout expected December 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track MDWD biotech catalysts?→
Add MDWD to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow MediWound Ltd.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.